Table 2.
Compliance, persistence, and metabolic control according to the study groups
| Study groups
|
Metformin + OA
|
Metformin + vildagliptin
|
Total
|
P-value |
|---|---|---|---|---|
| Patients, n (%) | n=717 | n=270 | n=987 | |
| Months on metformin | 29 (14.2) | 25.9 (12.1) | 28.1 (13.7) | 0.002 |
| Metformin use >1 year | 76.3% | 73.6% | 75.7% | <0.001 |
| Months of associated treatment | ||||
| Mean (SD) | 19.3 (7.1) | 21.2 (5.1) | 20.0 (6.8) | <0.001 |
| Median (P25–P75) | 21.0 (10.0–23.0) | 22.0 (17.0–24.0) | 22.0 (13.0–23.0) | <0.001 |
| Therapeutic compliance | 62.5% | 68.3% | 64.1% | 0.002 |
| ≥80%, high | 49.1% | 55.1% | 51.4% | |
| 50%–79%, medium | 30.7% | 29.1% | 30.3% | |
| <50%, low | 20.2% | 15.8% | 18.2% | <0.001 |
| Treatment persistence | 55.1% | 61.5% | 56.1% | 0.031 |
| Metabolic control | ||||
| Initial period | 55.7% | 58.8% | 56.5% | 0.360 |
| Final period | 57.6% | 63.3% | 59.4% | |
| Difference in percentages | 1.9% | 4.5% | 2.9% | 0.022 |
Notes: Values expressed as a percentage or mean (standard deviation); treatment persistence was defined as the time without abandonment of initial treatment or with no change to other medication for at least 30 days after the initial prescription; metabolic control was defined as glycosylated hemoglobin <7%.
Abbreviations: OA, oral antidiabetics, includes sulfonylureas and glitazones; SD, standard deviation; P, percentile.